, Enfin, l'utilisation croissante des CAR-T cell (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene) chez l'adulte en troisième ligne thérapeutique est en plein essor d'utilisation

, L'activité antigénique des lymphocytes modulés anti-CD19 semblent indépendante d'un profil phénotypique (COO) ou moléculaire (HGBCL) 12,13 donnés

, Annexe 2 Caractéristiques générales (COO, séquençage, matériel, cytogénétique, survie) de la cohorte d'analyse. DMP : dossier médical patient ; # : référence patient ; H : homme ; F : femme 8 REFERENCES BIBLIOGRAPHIQUES 1

R. I. Fisher, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N. Engl. J. Med, vol.328, pp.1002-1006, 1993.

B. Coiffier, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, N. Engl. J. Med, vol.346, pp.235-242, 2002.

C. Récher, Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an openlabel randomised phase 3 trial, The Lancet, vol.378, pp.1858-1867, 2011.

I. T. Gavrilovic, A. Hormigo, J. Yahalom, L. M. Deangelis, and L. E. Abrey, Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma, J. Clin. Oncol, vol.24, pp.4570-4574, 2006.

A. Chiappella, Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?: HemaSphere, vol.3, p.284, 2019.

F. Reyes, ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma, N. Engl. J. Med, vol.352, pp.1197-1205, 2005.

M. Crump, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, Blood, vol.130, pp.1800-1808, 2017.

H. Hagberg and C. Gisselbrecht, Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study, Ann. Oncol, vol.17, pp.31-32, 2006.

T. Philip, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N. Engl. J. Med, vol.333, pp.1540-1545, 1995.

C. Gisselbrecht, Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 + Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma, J. Clin. Oncol, vol.30, pp.4462-4469, 2012.

R. J. Van-kampen, Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry, J. Clin. Oncol, vol.29, pp.1342-1348, 2011.

F. L. Locke, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, vol.20, pp.31-42, 2019.

S. J. Schuster, Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma, N. Engl. J. Med, vol.380, pp.45-56, 2019.

C. Barrenetxea-lekue, Pixantrone beyond monotherapy: a review, Ann. Hematol, vol.98, pp.2025-2033, 2019.

H. Tilly, Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study, Lancet Oncol, vol.20, pp.998-1010, 2019.


S. Dubois, Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02327300

M. S. Lionakis, Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma, Cancer Cell, vol.31, p.5, 2017.

C. L. Batlevi, A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma, Br. J. Haematol, vol.178, pp.434-441, 2017.

G. S. Nowakowski, Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study, J. Clin. Oncol, vol.33, pp.251-257, 2015.

S. M. Ansell, Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study, J. Clin. Oncol, vol.37, pp.481-489, 2019.

G. Lenz, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proc. Natl. Acad. Sci. 105, pp.13520-13525, 2008.

W. Klapper, Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma, Blood, vol.119, pp.1882-1887, 2012.

R. E. Davis, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, vol.463, pp.88-92, 2010.

A. Mottok, Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens, Blood, vol.132, pp.2401-2405, 2018.

S. Mareschal, Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study, J. Mol. Diagn, vol.17, pp.273-283, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01145953

R. D. Morin, Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, vol.122, pp.1256-1265, 2013.

M. Compagno, Mutations of multiple genes cause deregulation of NF-?B in diffuse large B-cell lymphoma, Nature, vol.459, pp.717-721, 2009.

L. Pasqualucci and R. Dalla-favera, Genetics of diffuse large B-cell lymphoma, Blood, vol.131, pp.2307-2319, 2018.

R. M. Young, A. L. Shaffer, J. D. Phelan, and L. M. Staudt, B-cell receptor signaling in diffuse large B-cell lymphoma, Semin. Hematol, vol.52, pp.77-85, 2015.

A. Reddy, Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma, Cell, vol.171, p.15, 2017.

B. Chapuy, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat. Med, vol.24, pp.679-690, 2018.

R. Schmitz, Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma, N. Engl. J. Med, vol.378, pp.1396-1407, 2018.

S. Dubois, Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles, EBioMedicine, vol.48, pp.58-69, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02345428

C. Sha, Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy, J. Clin. Oncol, vol.37, pp.202-212, 2019.

D. Ennishi, Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, J. Clin. Oncol, vol.37, pp.190-201, 2019.

M. Schwaederle, Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials, J. Clin. Oncol, vol.33, pp.3817-3825, 2015.

L. Tourneau and C. , Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-ofconcept, randomised, controlled phase 2 trial, Lancet Oncol, vol.16, pp.1324-1334, 2015.

J. P. Leonard, Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma, J. Clin. Oncol, vol.35, pp.3538-3546, 2017.

A. Younes, Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma, J. Clin. Oncol, vol.37, pp.1285-1295, 2019.


S. Dubois, Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study, Clin. Cancer Res, vol.22, pp.2919-2928, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01343064

A. Rosenwald, Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium, J. Clin. Oncol, vol.37, pp.3359-3368, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02328933

M. Pfreundschuh, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), Lancet Oncol, vol.9, pp.105-116, 2008.

R. M. Young, Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy, Annu. Rev. Cancer Biol, vol.3, pp.429-455, 2019.

Y. Cao, Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors, Oncotarget, vol.7, 2016.

V. Hoff and D. D. , Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers, J. Clin. Oncol, vol.28, pp.4877-4883, 2010.

K. Do, G. O. Coyne, and A. P. Chen, An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin, Clin. Oncol, vol.4, 2015.

J. K. Sicklick, Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study, Nat. Med, vol.25, pp.744-750, 2019.

C. Massard, High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov, vol.7, pp.586-595, 2017.

F. André, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, vol.15, pp.267-274, 2014.

A. Davies, Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial, Lancet Oncol, vol.20, pp.649-662, 2019.

U. Vitolo, ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R 2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma, Hematol. Oncol, vol.37, pp.36-37, 2019.

P. Sujobert, Definition of a minimal genes set for mature lymphoid blood diseases, Hématologie, vol.24, pp.27-59, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01870189